135 related articles for article (PubMed ID: 36038117)
1. Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis.
Lee EJ; Duggirala KB; Lee Y; Yun MR; Jang J; Cyriac R; Jung ME; Choi G; Chae CH; Cho BC; Lee K
Bioorg Med Chem Lett; 2022 Nov; 75():128956. PubMed ID: 36038117
[TBL] [Abstract][Full Text] [Related]
2. Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition.
Hamada S; Matsumoto R; Tanaka Y; Taguchi K; Yamamoto M; Masamune A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672789
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
Elgogary A; Xu Q; Poore B; Alt J; Zimmermann SC; Zhao L; Fu J; Chen B; Xia S; Liu Y; Neisser M; Nguyen C; Lee R; Park JK; Reyes J; Hartung T; Rojas C; Rais R; Tsukamoto T; Semenza GL; Hanes J; Slusher BS; Le A
Proc Natl Acad Sci U S A; 2016 Sep; 113(36):E5328-36. PubMed ID: 27559084
[TBL] [Abstract][Full Text] [Related]
5. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.
Shukla K; Ferraris DV; Thomas AG; Stathis M; Duvall B; Delahanty G; Alt J; Rais R; Rojas C; Gao P; Xiang Y; Dang CV; Slusher BS; Tsukamoto T
J Med Chem; 2012 Dec; 55(23):10551-63. PubMed ID: 23151085
[TBL] [Abstract][Full Text] [Related]
7. Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.
Zimmermann SC; Duvall B; Tsukamoto T
J Med Chem; 2019 Jan; 62(1):46-59. PubMed ID: 29969024
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for exploring the allosteric inhibition of human kidney type glutaminase.
Ramachandran S; Pan CQ; Zimmermann SC; Duvall B; Tsukamoto T; Low BC; Sivaraman J
Oncotarget; 2016 Sep; 7(36):57943-57954. PubMed ID: 27462863
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
10. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.
Best SA; Gubser PM; Sethumadhavan S; Kersbergen A; Negrón Abril YL; Goldford J; Sellers K; Abeysekera W; Garnham AL; McDonald JA; Weeden CE; Anderson D; Pirman D; Roddy TP; Creek DJ; Kallies A; Kingsbury G; Sutherland KD
Cell Metab; 2022 Jun; 34(6):874-887.e6. PubMed ID: 35504291
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous inhibition of PFKFB3 and GLS1 selectively kills KRAS-transformed pancreatic cells.
Ozcan SC; Mutlu A; Altunok TH; Gurpinar Y; Sarioglu A; Guler S; Muchut RJ; Iglesias AA; Celikler S; Campbell PM; Yalcin A
Biochem Biophys Res Commun; 2021 Sep; 571():118-124. PubMed ID: 34325126
[TBL] [Abstract][Full Text] [Related]
12. Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate.
Wu B; Liu J; Zhao R; Li Y; Peer J; Braun AL; Zhao L; Wang Y; Tong Z; Huang Y; Zheng JC
J Neuroinflammation; 2018 Mar; 15(1):79. PubMed ID: 29540215
[TBL] [Abstract][Full Text] [Related]
13. BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase.
Hartwick EW; Curthoys NP
J Enzyme Inhib Med Chem; 2012 Dec; 27(6):861-7. PubMed ID: 21999665
[TBL] [Abstract][Full Text] [Related]
14. Effect of lysine to alanine mutations on the phosphate activation and BPTES inhibition of glutaminase.
McDonald CJ; Acheff E; Kennedy R; Taylor L; Curthoys NP
Neurochem Int; 2015 Sep; 88():10-4. PubMed ID: 25510640
[TBL] [Abstract][Full Text] [Related]
15. Full-length human glutaminase in complex with an allosteric inhibitor.
DeLaBarre B; Gross S; Fang C; Gao Y; Jha A; Jiang F; Song J J; Wei W; Hurov JB
Biochemistry; 2011 Dec; 50(50):10764-70. PubMed ID: 22049910
[TBL] [Abstract][Full Text] [Related]
16. Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators.
Stalnecker CA; Erickson JW; Cerione RA
J Biol Chem; 2017 Apr; 292(15):6095-6107. PubMed ID: 28196863
[TBL] [Abstract][Full Text] [Related]
17. Glutaminase 1 Inhibition Reduces Glycolysis and Ameliorates Lupus-like Disease in MRL/lpr Mice and Experimental Autoimmune Encephalomyelitis.
Kono M; Yoshida N; Maeda K; Suárez-Fueyo A; Kyttaris VC; Tsokos GC
Arthritis Rheumatol; 2019 Nov; 71(11):1869-1878. PubMed ID: 31233276
[TBL] [Abstract][Full Text] [Related]
18. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism.
Thangavelu K; Pan CQ; Karlberg T; Balaji G; Uttamchandani M; Suresh V; Schüler H; Low BC; Sivaraman J
Proc Natl Acad Sci U S A; 2012 May; 109(20):7705-10. PubMed ID: 22538822
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a novel glutaminase inhibitor.
Cederkvist H; Kolan SS; Wik JA; Sener Z; Skålhegg BS
FEBS Open Bio; 2022 Jan; 12(1):163-174. PubMed ID: 34698439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
